Moricizine (HCl)
Generic medicine reference
Not yet clinically reviewed
This entry was migrated from the earlier Pharmapedia app bundle and has not been reviewed by a named clinician on this site. It is provided for educational reference only — verify dosage and safety information against current, authoritative sources and a qualified healthcare professional before any clinical use.
Overview
Moricizine (HCl) is an oral class I antiarrhythmic agent, chemically unrelated to any other antiarrhythmic drugs. Classification of moricizine within the group of class I antiarrhythmics is difficult since the drug has features of all three subclasses, class Ia, Ib, and Ic. Although chemically related to phenothiazines, moricizine has no central or peripheral dopamine blocking activity. Moricizine (HCl) is reserved for the treatment of life-threatening ventricular arrhythmias. Moricizine was originally synthesized in the Soviet Union in 1964 and has been in use there since 1971. Moricizine was FDA approved on June 19, 1990. Moricizine (HCl) is currently only available as oral tablets.
Indications
Moricizine (HCl) is primarily indicated in conditions like Atrial arrhythmias, Ventricular arrhythmias.
Contraindications
Moricizine (HCl) is contraindicated in conditions like Cardiogenic shock, Sick sinus syndrome, Hypersensitivity, Second or third degree A-V block.
Side Effects
The severe or irreversible adverse effects of Moricizine (HCl), which give rise to further complications include Seizures, Sinus bradycardia, Respiratory depression. Moricizine (HCl) produces potentially life-threatening effects which include Ventricular arrhythmias, Pro-arrhythmogenicity, Elevated creatine phosphokinase ESR. which are responsible for the discontinuation of Moricizine (HCl) therapy. The signs and symptoms that are produced after the acute overdosage of Moricizine (HCl) include Cardiac arrhythmias. The symptomatic adverse reactions produced by Moricizine (HCl) are more or less tolerable and if they become severe, they can be treated symptomatically, these include Weakness, Dizziness, Headache, Drowsiness, Fatigue, Nausea, Vomiting, Diarrhea, Fever, Anxiety, Dyspnea, Restlessness, Palpitation, Constipation, Abdominal pain, Dry mouth, Blurred vision, Confusion, Dyspepsia, Sleep disturbance, Tremor, Paresthesias, Musculoskeletal pain.
Warnings
Electrolyte imbalance should be corrected before initiating therapy. It should be used with caution in patients with pace makers, with pronounced hepatic function, with G6PD deficiency. Reduction in dosage may be necessary in patients with impaired renal function. Topically it should be used with caution in patients with hepatic disease or impairment. It is classified as category B for use during pregnancy. It should be used only when clearly needed during pregnancy.
High Risk Groups
If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.
Adult Dosage
No adult dosage information is recorded for this medicine yet.
Child Dosage
No child dosage information is recorded for this medicine yet.
Neonatal Dosage
No neonatal dosage information is recorded for this medicine yet.
Drug Interactions
Moricizine (HCl) is known to interact with other drugs, the details of drug interactions is as follows:DrugDetailsSeverityOnsetManagementCimetidine (HCl)DigoxinTheophyllineVORICONAZOLEVoriconazole may increase the serum concentration of moricizine by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects These interactions are sometimes beneficial and sometimes may pose threats to life. Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.
Storage
Tab Store Between 15°C-25°C. Protect from Sunlight.
Available Brands in Pakistan
No brands are recorded for this generic.